Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Expands By 606.2%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 289,957 shares, an increase of 606.2% from the June 15th total of 41,058 shares. Currently, 8.5% of the company’s shares are sold short. Based on an average daily trading volume, of 18,514,293 shares, the days-to-cover ratio is presently 0.0 days.

Catheter Precision Trading Down 30.7%

Shares of Catheter Precision stock traded down $0.35 during midday trading on Friday, reaching $0.79. 2,388,087 shares of the company’s stock traded hands, compared to its average volume of 20,266,990. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.06 and a current ratio of 0.06. The company has a market cap of $2.85 million, a PE ratio of -0.06 and a beta of -1.07. The stock has a 50 day moving average of $0.92 and a 200-day moving average of $1.32. Catheter Precision has a 12 month low of $0.61 and a 12 month high of $4.94.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its quarterly earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent reporting period. 20.34% of the stock is currently owned by institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.